Saturday, 01 April 2023 07:10
RIVERSTONE FALLS TO LABOR, BALI RETURNED
Chamber man prevails in politics
RIVERSTONE is one of the surprise seats Labor snatched from the Liberals at the March 25 NSW election, bringing businessman Warren Kirby into the fold.
Published in
Default Set
Thursday, 30 March 2023 14:03
GOVERNMENT DELIVERING ON CHILDCARE
VIEWPOINT: Support for early learning good for all
MICHELLE ROWLAND
MICHELLE ROWLAND
SUPPORTING early learning is good for families, good for young ones, and good for the national economy.
Published in
Default Set
Thursday, 30 March 2023 12:31
PBS CRITERIA EXPANDED FOR COVID-19 ORAL ANTI-VIRAL
FROM April 1, 2023, the eligibility criteria for access to PAXLOVID™ (nirmatrelvir tablets and ritonavir tablets) on the Pharmaceutical Benefits Scheme (PBS) will be expanded to include people between 60-69 years of age with mild to moderate COVID-19 with one additional risk factor for developing severe disease.
Pfizer Australia and New Zealand Medical Director, Dr Krishan Thiru, said: “As winter approaches, we anticipate a heightened impact of COVID-19 in the community, as has occurred in the previous three years. This widening of PBS eligibility criteria means many more Australians most at risk of severe disease may be able to access PAXLOVID through the PBS if they test positive for COVID-19, and take treatment at home.”
PAXLOVID is a prescription only oral medicine taken twice-daily for five days. It should be taken as soon as possible after a diagnosis of COVID-19, and within five days of symptoms appearing.
Published in
Default Set